Cure My Disease

Don't miss your cure!

 Log in / Sign up

Infusion or bolus? study tests best steroid delivery for septic shock

NCT ID NCT07695337

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial compares two methods of giving hydrocortisone to adults with septic shock—a life-threatening drop in blood pressure due to infection. One group receives the steroid as a continuous drip, the other as intermittent shots every six hours. Researchers track 28-day survival, shock reversal, and recovery times to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hydrocortisone
What this could lead to
If one method proves better, it could become the standard way to give hydrocortisone for septic shock, potentially saving more lives.
What could go wrong
This is a single-center trial with 110 participants, so results may not apply broadly. The two methods may turn out to be equally effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

110 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older of either sex. * Diagnosis of septic shock according to Sepsis-3 criteria, defined as sepsis with persistent hypotension requiring vasopressor therapy to maintain a mean arterial pressure of at least 65 mmHg and a serum lactate level greater than 2 mmol/L despite adequate fluid resuscitation. * Admission to the intensive care unit at Benha University Hospitals. Exclusion Criteria: * Known allergy or contraindication to hydrocortisone. * Known adrenal insufficiency. * Chronic systemic corticosteroid therapy for more than 1 month before enrollment. * Pregnancy or lactation. * Active gastrointestinal bleeding. * Immunosuppression. * Expected survival of less than 24 hours or imminent death from a non-infectious cause. * Psychiatric disorder that could interfere with study participation. * Coagulation disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

Contacts and locations

Locations

  • Benha University Hospitals

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.